- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.09. | Sanuwave Health verstößt gegen Nasdaq-Börsenregeln: Marktkapitalisierung zu gering | 3 | Investing.com Deutsch | ||
| 25.09. | SANUWAVE Health, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 07.08. | Sanuwave withdraws FY2026 revenue guidance amid CMS proposal implying 97610 reimbursement of $316.59 in 2027 | 16 | Seeking Alpha | ||
| 07.08. | Sanuwave Q2 2026 slides: consumables rise as system sales slide | 1 | Investing.com | ||
| 07.08. | SANUWAVE Health GAAP EPS of -$0.08, revenue of $9.74M | 1 | Seeking Alpha | ||
| 06.08. | SANUWAVE Health, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| SANUWAVE HEALTH Aktie jetzt für 0€ handeln | |||||
| 06.08. | SANUWAVE Health, Inc.: Sanuwave Announces Q2 FY2026 Financial Results | 178 | GlobeNewswire (Europe) | Q2 2026 revenues were $9.7 million, down 3% from $10.1 million in Q2 2025. Q2 2026 gross margin was 76.2%, versus 78.1% in Q2 2025. GAAP Operating (Loss) Income was $(0.3) million for Q2 2026... ► Artikel lesen | |
| 06.08. | SANUWAVE Health, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.07. | Sanuwave sees Q2 revenue up to $9.8M | 1 | Seeking Alpha | ||
| 13.07. | Sanuwave: Q2-Umsatz übertrifft Prognose | 3 | Investing.com Deutsch | ||
| 13.07. | Sanuwave posts Q2 revenue of $9.6M-$9.8M, beating guidance | 1 | Investing.com | ||
| 13.07. | SANUWAVE Health, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.07. | SANUWAVE Health, Inc.: Sanuwave Health Reports Preliminary Q2 2026 Revenue of $9.6-$9.8 Million, Above High End of Revised Guidance | 1.053 | GlobeNewswire (Europe) | EDEN PRAIRIE, Minn., July 13, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave") (NASDAQ: SNWV), a leading provider of FDA-cleared directed energy systems used in advanced... ► Artikel lesen | |
| 16.06. | SANUWAVE Health, Inc.: Sanuwave Health Updates Second Quarter 2026 Guidance | 270 | GlobeNewswire (Europe) | Sanuwave updates guidance for Q2 2026 to $8.5 - $9.5 million Company on pace for record unit sales of applicators in Q2 Market disruption impacting Ultramist system sales EDEN PRAIRIE, Minn., June... ► Artikel lesen | |
| 15.06. | SANUWAVE Health, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.05. | Sanuwave forecasts Q2 revenue of $11.1M-$11.6M while maintaining $51M-$55M full-year outlook | 1 | Seeking Alpha | ||
| 13.05. | SANUWAVE Health Inc Reports Q1 2026 Results: Full Earnings Call Transcript | 3 | Benzinga.com | ||
| 13.05. | SANUWAVE Health reports mixed Q1 results; initiates Q2 and reaffirms FY26 outlook | 2 | Seeking Alpha | ||
| 12.05. | SANUWAVE Health, Inc.: Sanuwave Announces Revenues and Financial Results for Q1 FY2026 | 257 | GlobeNewswire (Europe) | Q1 2026 revenues were $9.6 million, up 3.1% from $9.3 million in Q1 2025. This represents the highest Q1 quarterly revenues in Company history. Q1 2026 gross margin was 77.3%, versus 79.0% in Q1 2025.... ► Artikel lesen | |
| 12.05. | SANUWAVE Health, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TELADOC HEALTH | 5,034 | +1,99 % | Teladoc Health Adds Contactless Vitals and Ambient AI Scribe to Virtual Visit Platform | ||
| SERNOVA BIOTHERAPEUTICS | 0,065 | -11,92 % | Sernova Biotherapeutics, Inc.: Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial | TORONTO and GERMANTOWN, Md., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. ("Sernova") (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO) and Seraxis Holdings, Inc. ("Seraxis") today announced... ► Artikel lesen | |
| CERENOME | 1,504 | +10,43 % | Cerenome, Inc.: Cerenome Launches CNSide CSF Molecular Profile Tests | HOUSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), today announced the commercial launch... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 2,180 | +0,93 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update | SEATTLE, Aug. 7, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -5- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS75973T2006 RENALYTIX... ► Artikel lesen | |
| TANDEM DIABETES | 13,500 | -3,57 % | Tandem Diabetes Care, Inc.: Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets | Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that Tandem Mobi, the world's smallest, durable automated insulin delivery... ► Artikel lesen | |
| CO-DIAGNOSTICS | 1,095 | +0,46 % | Co-Diagnostics Reports Second Quarter 2026 Financial Results | Advancing Commercialization Through FDA Submission, Global Clinical Progress and Manufacturing Expansion
Strengthening Integrated Co-Dx PCR Platform Through Scientific... ► Artikel lesen | |
| QUIDELORTHO | 10,840 | -2,03 % | Sanjeev Sharma wird neuer Leiter Investor Relations bei QuidelOrtho | ||
| VERU | 2,405 | -0,62 % | Veru Inc.: Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines' RASONQUE) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial | ||
| LIFEWARD | 6,510 | 0,00 % | Lifeward Ltd. - 8-K, Current Report | ||
| CLOVER HEALTH INVESTMENTS | 4,470 | +9,29 % | Clover Health Investments, Corp.: Clover Health Medicare Advantage PPO Plans Earn 5 Star Rating for 2027 | ||
| SENSEONICS | 7,950 | -1,24 % | Beta Bionics, Inc.: Beta Bionics Announces Agreement Integrate the iLet Bionic Pancreas and mint with Senseonics' Eversense 365 | IRVINE, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced a partnership... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 0,766 | -0,51 % | Tempest Therapeutics beruft Nancy Freda-Smith in den Verwaltungsrat | ||
| NANO-X IMAGING | 0,565 | -0,25 % | Nano-X Imaging Ltd: Nanox Expands Latin American Presence with Nanox.ARC Distribution Agreement in Costa Rica | Agreement with SOLME RC, SA Marks the third Latin American market this year PETACH TIKVA, Israel, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Nanox Imaging Ltd. (NASDAQ: NNOX) ("Nanox"), a leader in innovative... ► Artikel lesen | |
| IMUNON | 0,935 | 0,00 % | Imunon, Inc.: IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer | Enrollment momentum exceeding expectations is based on highly promising survival (OS) data and well tolerated safety profile demonstrated in the Company's large, randomized Phase II study, OVATION... ► Artikel lesen |
SANUWAVE HEALTH INC gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 5,860 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SANUWAVE HEALTH INC finden Sie auf Wallstreet Online.